COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,673 Articles (22,913 medRxiv, 8,760 bioRxiv)

Most recent first Previous |  Page 1788: Articles 17871-17880  | Next

Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study.
Silva, M., Espejo, A., Pereyra, M. L., Lynch, M., Thompson, M., Taconelli, H., Bare, P., Pereson, M., Garbini, M., Crucci, P., Enriquez, D.
10.1101/2021.03.03.21252509 — Posted: 2021-03-05
Kinetics of SARS-CoV-2 anti-s IgG after BNT162b2 vaccination
Grupel, D., Gazit, S., Schreiber, L., Nadler, V., Wolf, T., Lazar, R., Supino-Rosin, L., Perez, G., Peretz, A., Ben Tov, A., Mizrahi-Reuveni, M., Chodick, G., Patalon, T.
10.1101/2021.03.03.21252844 — Posted: 2021-03-05
Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™ - Antigen-detecting point-of-care device for SARS-CoV-2
Krüger, L. J., Klein, J. A. F., Tobian, F., Gaeddert, M., Lainati, F., Klemm, S., Schnitzler, P., Bartenschlager, R., Cerikan, B., Neufeldt, C., Nikolai, O., Lindner, A., Mockenhaupt, F. P., Seybold, J., Jones, T. C., Corman, V. M., Pollock, N. M., Knorr, B., Welker, A., de Vos, M., Sacks, J. A., Denkinger, C. M.
10.1101/2021.03.02.21252430 — Posted: 2021-03-05
An Explainable Artificial Intelligence based Prospective Framework for COVID-19 Risk Prediction
Sharma, V., , P., Chhatwal, S., Singh, B.
10.1101/2021.03.02.21252269 — Posted: 2021-03-05
Economic Benefits of COVID-19 Screening Tests with a Vaccine Rollout
Atkeson, A., Droste, M. C., Mina, M. J., Stock, J.
10.1101/2021.03.03.21252815 — Posted: 2021-03-05
Covid-19 impact on Parkinson's Disease patients treated by drugs or deep brain stimulation
Salari, M., Etemadifar, M., Zali, A., Aminzade, Z., Farsinejad, P., Tehrani Fateh, S.
10.1101/2021.03.03.21252464 — Posted: 2021-03-05
Comparing Vaccination Strategies in Canada Under Different Assumptions
Ruse, T.
10.1101/2021.03.02.21252761 — Posted: 2021-03-05
Schooling amidst a pandemic: parents' perceptions about reopening schools and anticipated challenges during COVID-19
Meghani, A., Agarwal, S., Zapf, A. J., Edwards, J., Labrique, A. B., Gibson, D. G.
10.1101/2021.03.02.21252777 — Posted: 2021-03-05
Sharing positive changes made during COVID-19 national lockdown: a multi-method co-production study
Williams, L., MacDonald, B., Rollins, L., Janssen, X., Fleming, L., Grealy, M., Kirk, A., Young, D., Flowers, P.
10.1101/2021.03.03.21252809 — Posted: 2021-03-05
Self-reported symptoms, self-reported viral testing result and seroprevalence of SARS CoV-2 among a community sample in Essex County New Jersey: A brief report.
Raymond, H. F., Datta, P., Ukey, R., Wang, P., Martino, R. J., Krause, K. D., Rosmarin-DeStefano, C., Pinter, A., Halkitis, P. N., Gennaro, M. L.
10.1101/2021.03.02.21252766 — Posted: 2021-03-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).